Position statement for isotretinoin

Journal of Cutaneous Medicine and Surgery

Volumn 11, Issue 3, 2007, Pages 123-124

  Gupta, Aditya K ^a,b   Lynde, Charles W ^a   Poulin, Yves ^a   Smith, Kevin ^a   Lewis, Richard ^a   Zip, Catherine ^a  

^a Canadian Dermatology Association   (Canada)

^b NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GENERIC DRUG; ISOTRETINOIN; DERMATOLOGICAL AGENT;

ACNE; ACNE CONGLOBATA; ACNE CYSTICA; ADVISORY COMMITTEE; ARTICLE; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; HUMAN; INFORMED CONSENT; PREGNANCY DISORDER; PRESCRIPTION; PRIORITY JOURNAL; RECALCITRANT ACNE; RISK FACTOR; SCAR FORMATION; SUICIDAL BEHAVIOR; CANADA; DRUG INFORMATION; FEMALE; INTERNET; PRACTICE GUIDELINE; PREGNANCY; PREGNANCY TEST; RISK MANAGEMENT; UNITED STATES;

CANADA; CONSENT FORMS; DERMATOLOGIC AGENTS; DRUG INFORMATION SERVICES; FEMALE; HUMANS; INTERNET; ISOTRETINOIN; PREGNANCY; PREGNANCY TESTS; PRESCRIPTIONS, DRUG; RISK MANAGEMENT; UNITED STATES;

EID: 34548607354     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.2310/7750.2007.00017     Document Type: Article

References (3)

1. Hoffman-Roche Laboratories Ltd. Accutane™ Roche® (Isotretinoin) 10mg and 40mg capsules [product monograph]. 2005.
2. US Food and Drug Administration. FDA public health advisory: Accutane (Isotretinoin). Available at: www.fda.gov/cder/drug/advisory/ isotretinoin2005.htm (accessed October 28, 2005).
3. Roche Products Limited. Roaccutane 5mg and 20mg soft capsules [package leaflet]. 2005.